ClinicalTrials.gg
Not yet recruitingNCT07548957Updated Apr 23, 2026

A Study to Evaluate the Safety and Pharmacokinetics of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy Adult Volunteers Under Fasting Conditions

A Phase 1 interventional study of Administration of UI087 and Administration of UIC202506, UIC202507, UIC202508 in Diabetes Mellitus (Type 2), sponsored by Korea United Pharm. Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Korea United Pharm. Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of — 70 open to participants now, 84 under way, 26 of them phase 3. Diabetes Mellitus, Type 2 · Korea, Republic of.

Planned enrollment
384th of 493
44 · median 174
Started
2026
with 29 others
Phase 1
95 of 571
8 open now
Primary completion
2026-08
later than 30 of 83 live
Registered
547th of 571
by date

Among the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, this one is the 384th largest by planned enrollment of the 493 interventional ones that give a count, is one of 30 that started in 2026, is one of 95 in phase 1, reaches primary completion later than 30 of the 83 other live ones, and was the 547th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

70 of the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study was an open-label, randomized, single-dose, 2-sequence, 2-period, crossover study to evaluate the safety and pharmacokinetics of UI087 compared to coadministration of UIC202506, UIC202507 and UIC202508 in healthy adult volunteers under fasting conditions

03

Conditions studied

  • Diabetes Mellitus (Type 2)
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 19 years or older at the screening visit
  • Subjects with a body weight ≥ 50 kg (≥ 45 kg for females) and a (BMI) between 18.0 and 30.0 kg/m² at the screening visit

    • BMI (kg/m²) = body weight (kg) / {height (m)}²
  • Subjects without congenital or chronic diseases and without pathological symptoms or findings based on medical examination at the screening visit
  • Subjects deemed eligible for participation based on diagnostic tests (hematology, blood chemistry, serology, urinalysis, etc.) and , as determined by the investigator (or delegated sub-investigator) according to the characteristics of the product
  • Subjects who agree to use medically acceptable * (excluding hormonal methods) from the first dose until 7 weeks after the last dose of the investigational product, to prevent pregnancy for themselves or their spouse/partner, and who agree not to donate sperm or ova

    • Medically acceptable contraception: Use of intrauterine devices, vasectomy, tubal ligation, and/or barrier methods (male condom, female condom, cervical cap, diaphragm, sponge, etc.), or the use of spermicide in combination with at least two barrier methods
  • Subjects who voluntarily sign the form after receiving and fully understanding sufficient explanation regarding the purpose, procedures, characteristics of the investigational product, and expected adverse events of the clinical trial

Exclusion criteria

Exclusion Criteria:

  • Subjects with diseases or a history of diseases involving the gastrointestinal, cardiovascular, endocrine, respiratory, hematologic/oncologic, infectious, renal and genitourinary, psychiatric/neurological, musculoskeletal, immune, ENT, dermatologic, or ophthalmologic systems
  • Subjects with a history of gastrointestinal surgery (excluding simple appendectomy or hernia repair) that may affect drug absorption, or with gastrointestinal diseases
  • Subjects who have taken enzyme-inducing or inhibiting drugs (e.g., barbiturates) within 1 month prior to the first dose, or medications that may affect the clinical trial within 10 days prior to the first dose (Participation may be allowed depending on pharmacokinetic/pharmacodynamic properties such as interactions and half- life)
  • Subjects who have participated in another clinical trial or bioequivalence study and received an product within 6 months prior to the first dose
  • Subjects who have donated whole blood within 8 weeks, donated blood components within 2 weeks, or received a transfusion within 4 weeks prior to the first dose
  • Subjects meeting the following conditions within 1 month prior to the first dose:

    • Alcohol consumption exceeding an average of 21 drinks/week for males
    • Alcohol consumption exceeding an average of 14 drinks/week for females

      (1 drink = 50 mL of soju, 30 mL of spirits, or 250 mL of beer)

    • Smoking more than an average of 20 cigarettes per day
  • Subjects who meet the following:

    • to the active ingredient, of the investigational product, or a drug in the same class as the investigational product
    • Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  • Subjects with the following conditions:

    • Type 1 diabetes mellitus, lactic acidosis, or acute/chronic metabolic acidosis including diabetic ketoacidosis (with or without coma), or a history of ketoacidosis
    • Moderate (stage 3b) or severe renal impairment ( \< 45 mL/min/1.73 m²), or acute conditions that may affect renal function such as dehydration, severe infection, cardiovascular collapse (shock), acute myocardial infarction, or sepsis
    • Acute or unstable heart failure
    • Patients undergoing intravascular iodinated contrast imaging (e.g., intravenous urography, cholangiography, angiography, contrast-enhanced CT, etc.)
    • Diabetic pre-coma
    • Severe infections or severe traumatic systemic disorders
    • Patients scheduled for surgery
    • Patients with malnutrition, starvation, debility, hypopituitarism, or adrenal insufficiency
    • Patients with acute or chronic conditions that may cause tissue hypoxia (e.g., hepatic impairment, respiratory failure, acute myocardial infarction, shock)
    • Patients with excessive alcohol intake or gastrointestinal disorders such as dehydration, diarrhea, or vomiting
  • Subjects deemed unsuitable for participation by the investigator (or delegated sub-investigator) for any other reason not specified above
  • Female subjects who are pregnant, suspected to be pregnant, or breastfeeding
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    UI087

    Test

    Drug: Administration of UI087

  • Active comparator
    UIC202506, UIC202507, UIC202508

    Reference

    Drug: Administration of UIC202506, UIC202507, UIC202508

Interventions

  • DrugAdministration of UI087

    1 tablet, once a day (Test)

  • DrugAdministration of UIC202506, UIC202507, UIC202508

    1 tablet, once a day (Reference)

06

What researchers measure

Primary outcomes

  1. AUCt

    Evaluation PK after single dose

    Time frame: 0 to 72 hours

  2. Cmax

    Evaluation PK after single dose

    Time frame: 0 to 72 hours

Secondary outcomes

  1. AUC∞

    Evaluation PK after single dose

    Time frame: 0 to 72 hours

  2. Tmax

    Evaluation PK after single dose

    Time frame: 0 to 72 hours

  3. t1/2

    Evaluation PK after single dose

    Time frame: 0 to 72 hours

  4. λz

    Evaluation PK after single dose

    Time frame: 0 to 72 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Aug 2026, 4 months later.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 4 months is below that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2026
First posted
Apr 23, 2026
StartEst.
Apr 2026
Primary completionEst.
Aug 2026
CompletionEst.
Oct 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07548957
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Apr 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Apr 23, 2026

Study contacts

SEUNG HYUN KANG, Ph.D.
Contact
juspa@newyjh.com
+82 070-4665-9490

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion